Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Daxor Corp (DXR)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
$8.63-3.14%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for DXR yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
EPS improves from -$0.21 to at least -$0.03 | A primary condition in Daxor Corp's published investment case. The stated target is >= -$0.03 EPS in FY27. | Intact | EPS remains below -$0.10 in FY27 | Diluted EPS: $-0.66 per share FY2026-Q2; GAAP. Published target: >= -$0.03 EPS in FY27. Annual target cannot be compared with a quarterly or TTM observation. Jun 30, 2026-0.66 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, smaller-cap healthcare name, and the available evidence does not establish a durable growth pattern or a turnaround. The thesis state is insufficient because there is not enough recent financial history to assess performance.
DXR’s valuation is above its peers, and the valuation measure rose from 59.9 to 70.0. The evidence does not specify what operating expectations support that premium, while no valuation fragility warnings were triggered.
Management is rated stable, and the healthcare sector backdrop is a tailwind. Near term, the estimated risk of missing expectations is low, but DXR’s smaller size and erratic earnings surprises remain concerns; the evidence gives little detail on its operating trajectory.
A weaker jobs trend could increase recession concerns and weigh on cyclical healthcare names like DXR. Continued earnings strength from sector bellwethers could sustain the sector tailwind, while misses or lower guidance from those companies could weaken it.
For the 1-to-3-year view, DXR’s thesis remains uncertain: sector support and stable management are balanced by high risk, a peer valuation premium, and limited financial evidence. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in Daxor Corp's published investment case. The stated target is FCF yield >= 0% next 4 quarters. |
| Broken |
| FCF yield remains below -2% over next 4 quarters |
Valuation inputs unavailable A completed valuation measurement is required. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Increase revenue from $11.9M to at least $20M | A primary condition in Daxor Corp's published investment case. The stated target is >= $20M revenue in FY27. | Intact | revenue falls below $15M in FY27 | Revenue: $23,020 FY2026-Q2; GAAP. Published target: >= $20M revenue in FY27. Annual target cannot be compared with a quarterly or TTM observation. Jun 30, 202623,020 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.03 → $-0.03 · observed estimates
$0.02B → $0.02B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-07-25 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-07-26 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-07-27 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-07-28 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-07-29 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-07-30 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-07-31 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-01 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-02 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-03 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-04 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-05 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-06 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-07 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-08 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-09 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-10 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-11 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-12 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-13 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-14 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-15 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-16 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-17 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-18 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-19 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-20 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-21 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-22 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-23 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-24 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-25 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-26 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-27 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-28 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-29 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-30 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-08-31 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-09-01 | $-0.03 | $20,800,000 | 1 / 1 |
| 2026-09-02 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-09-03 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-09-04 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-09-05 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-09-06 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-09-07 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-09-08 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-09-09 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-09-10 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-09-11 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-09-12 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-09-13 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-09-14 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-09-15 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-09-16 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-09-17 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-09-18 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-09-19 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-09-20 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-09-21 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-09-22 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-09-23 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-09-24 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-09-25 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-09-26 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-09-27 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-09-28 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-09-29 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-09-30 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-01 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-02 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-03 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-04 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-05 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-06 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-07 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-08 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-09 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-10 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-11 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-12 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-13 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-14 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-15 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-16 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-17 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-18 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-19 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-20 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-21 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-22 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-23 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-24 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-25 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-26 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-27 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-28 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-29 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-30 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-10-31 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-11-01 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-11-02 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-11-03 | $-0.03 | $16,399,999 | 1 / 1 |
| 2026-11-04 | $-0.03 | $16,399,999 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.